Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A 10 percent reduction in cancer-related deaths in the U.S. would be worth an estimated $4.4 trillion to current and future generations.  
  • Cancer Survival Rate Increasing  
  • Colorectal Cancer Screening: Trends, 2003-2006  
  • Cancer death rates for all races/ethnicities and both sexes combined decreased by 2.1% per year from 2002-2004, nearly twice the annual decrease of 1.1% per year from 1993-2002.  
  • Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months…